CytomX Therapeutics Stock Soars 94% On Positive Interim Phase 1 Data For Cancer Drug CX-2051

(RTTNews) - CytomX Therapeutics, Inc. (CTMX) jumped 94.55 percent to $1.78 in Monday trading after the company announced promising interim Phase 1 results for its EpCAM-targeting PROBODY ADC, CX-2051, in advanced colorectal cancer. The data demonstrated durable anti-tumor activity and tolerability in late-line metastatic CRC, an area with high unmet medical need.

The stock opened at $1.90 and traded between $1.65 and $2.18, a new 52-week high on the Nasdaq. Volume spiked to 90.9 million shares, far above its average of 2.4 million. CTMX previously closed at $0.93.

The results underscore the potential of CytomX's PROBODY technology to overcome long-standing challenges in targeting EpCAM, generating renewed investor enthusiasm.